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Abstract
Invasive group A streptococcal (iGAS) disease is endemic in Norway, but data on invasive group C and group G streptococcal (iGCS/
GGS) disease are lacking. We investigated the characteristics of iGAS and iGCS/GGS infections in western Norway from March 2006
to February 2009. Clinical information was retrospectively obtained from medical records. GAS and GCS/GGS isolates were emm typed
and screened for the presence of 11 superantigen (SAg) genes and the gene encoding streptococcal phospholipase A2 (SlaA). GCS/GGS
isolates were also subjected to PCR with primers targeting speGdys. Sixty iGAS and 50 iGCS/GGS cases were identiﬁed, corresponding
to mean annual incidence rates of 5.0 per 100 000 and 4.1 per 100 000 inhabitants, respectively. Skin and soft tissue infections were
the most frequent clinical manifestations of both iGAS and iGCS/GGS disease, and 14 iGAS patients (23%) developed necrotizing fasci-
itis. The 30-day case fatality rates of iGAS and iGCS/GGS disease were 10% and 2%, respectively. emm1, emm3 and emm28 accounted
for 53% of the GAS isolates, and these types were associated with severe clinical outcome. SAg gene and SlaA proﬁles were conserved
within most of the GAS emm types, although ﬁve proﬁles were obtained within isolates of emm28. stG643 was the most prevalent
GCS/GGS emm type, and speGdys was identiﬁed in 73% of the GCS/GGS isolates. Neither GAS SAg genes nor SlaA were detected in
GCS/GGS. Our ﬁndings indicate a considerable burden of both iGAS and iGCS/GGS disease and a high frequency of necrotizing fasciitis
caused by GAS in our community.
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Introduction
Subsequent to the resurgence of invasive group A strepto-
coccal (iGAS) disease in western countries from the mid
1980s, the epidemiology and pathogenesis of iGAS disease
has been extensively investigated [1,2]. Group C strepto-
cocci (GCS) and group G streptococci (GGS) causing
human disease are phylogenetically and clinically related to
GAS and are almost always of the species Streptococcus
dysgalactiae subsp. equisimilis. Traditionally, this species has
rarely been the cause of severe human infections. However,
during the last two decades, the incidence of invasive GCS/
GGS (iGCS/GGS) disease appears to have increased, and
has been comparable to that of iGAS disease in different
countries [3–6].
GAS and GCS/GGS share virulence factors, and among
them is the M protein. This multifunctional protein is
encoded by the emm gene. emm typing, based on the nucleo-
tide sequence in the hypervariable 5¢ end of the emm gene,
is a powerful epidemiological tool in surveys on streptococ-
cal disease. Streptococcal superantigens (SAgs) and strepto-
coccal phospholipase A2 (SlaA) are also important GAS
virulence factors [7,8]. SlaA and the majority of SAg genes
are found on phages, and both phage- and chromosomally-
encoded SAg genes have been involved in lateral genetic
transfers among GAS and GCS/GGS [9]. The relationship
between GAS virulence gene proﬁles and clinical syndromes
has previously been investigated, and emm types, such as
emm1/emm3, and SAg genes, such as speA/speC, have been
associated with severe clinical syndromes, such as necrotizing
fasciitis (NF) and streptococcal toxic shock syndrome (STSS)
[2,8,10]. However, data on comprehensive virulence gene
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proﬁling of iGCS/GGS isolates are relatively scarce [9,11–
13].
The incidence of iGAS disease has been high in Norway
during the last two decades [14,15], but data on iGCS/GGS
disease are lacking. In the present study, we have analyzed
the clinical and molecular characteristics of invasive b-hae-
molytic streptococcal disease in western Norway from
March 2006 to February 2009.
Materials and Methods
Study population and case deﬁnitions
All cases of iGAS and iGCS/GGS disease within the catch-
ment area of the Department of Bacteriology, Haukeland
University Hospital, from March 2006 to February 2009
were retrospectively registered. This laboratory receives
bacterial isolates from Haukeland University Hospital, Har-
aldsplass Deaconal Hospital and Voss Hospital. The popula-
tion in the catchment area increased from 397 000 to
411 500 inhabitants during the study period. Cases were
deﬁned by the isolation of GAS, GCS or GGS from a nor-
mally sterile site, or from a nonsterile site in association with
NF or STSS. NF was deﬁned as described previously [16],
and STSS was deﬁned using criteria originally meant for GAS
[17]. Severe sepsis was deﬁned as sepsis accompanied by
one or more signs of organ dysfunction [18]. Skin or soft
tissue infection (SSTI) included wound infection, erysipelas,
cellulitis and deep-seated abscesses. Patients were catego-
rized as having primary bacteremia if blood cultures were
positive and no source of infection was identiﬁed. Infections
were classiﬁed as nosocomial in patients hospitalized at least
48 h before their positive cultures were drawn.
Clinical information was obtained from medical records.
Demographics, diagnoses, comorbidities and information
about treatment and outcome were recorded, along with
clinical chemistry data and microbiological results. Informed
consent was obtained from all the patients. The study was
approved by the Regional Committee of Medical Research
Ethics.
Bacterial isolates
The isolates were identiﬁed in the Department of Bacteriol-
ogy at Haukeland University Hospital. Group carbohydrate
was ascertained using the Streptococcal Grouping kit (Oxoid
Ltd, Basingstoke, UK).
emm typing
emm typing was carried out as described previously [19], with
previously reported primers [20]. The 5¢ end of each sequence
was compared with sequences in the emm type database,
available on the CDC website (http://www.cdc.gov/ncidod/
biotech/strep/strepblast.htm). When a correct subtype assign-
ment could not be determined, the sequence trace was
submitted to the CDC for assignment of a new subtype.
Detection of SAg genes and SlaA
We used multiplex PCR with speciﬁc primers for the 11
GAS exotoxin genes speA, speC, speG, speH, speI, speJ, speK,
speL, speM, ssa and smeZ as described previously [21]. To
cover allelic variations of smeZ, a simplex PCR with previ-
ously reported primers was also used [22]. Simplex PCR
ampliﬁcations of speGdys, a speG orthologue found in Strepto-
coccus dysgalactiae subsp. equisimilis, and SlaA were performed
with primers described previously [11]. The speGdys primers
ampliﬁed segments of equal size in both speGdys and speG,
whereas the speG primers only ampliﬁed speG. Hence, all the
GAS and GCS/GGS were screened for the presence of the
11 GAS SAg genes and SlaA, whereas only the GCS/GGS
were subjected to PCR with the speGdys primers.
Statistical analysis
Categorical data were analyzed using Fisher’s exact test or
the chi-square test. Nonparametric data were analyzed using
the Mann–Whitney test. A two-sided p value £0.05 was con-
sidered statistically signiﬁcant.
Results
Epidemiology and clinical characteristics
A total of 110 cases were included. GAS, GCS and GGS
accounted for 60, four and 46 of these, respectively. Clinical
information was available for 109 patients. A total of 107 iso-
lates were available for analysis, and consisted of 59, three
and 45 of GAS, GCS and GGS, respectively. Among GAS, 48
isolates were from blood and 11 were from other sterile
sites (synovial/pleural/cerebrospinal ﬂuid or tissue biopsy).
Forty-two GGS were from blood and the remaining three
isolates were from bone (n = 2) and synovial ﬂuid (n = 1).
All three GCS were from blood.
The mean annual incidence of iGAS and iGCS/GGS
disease was 5.0 per 100 000 and 4.1 per 100 000 population,
respectively. Year-to-year variations were slight because the
annual incidence of iGAS disease was in the range 4.5–5.3
per 100 000 and that of iGCS/GGS infections in the range
3.6–4.8 per 100 000. Seasonal variations were observed, with
24% of the cases occurring during March to May, 18% during
June to August, 31% during September to November and
27% during December to February. Clinical characteristics of
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iGAS and iGCS/GGS disease are summarized in Tables 1 and
2. A high proportion of NF was observed in the iGAS group.
Four of the NF cases occurred during a 1-month period,
whereas the remaining 11 cases were distributed throughout
the rest of the study period. iGCS/GGS disease was associ-
ated with higher age, a larger proportion of male patients, a
higher prevalence of chronic heart disease and a higher fre-
quency of SSTI than iGAS disease. Although STSS (n = 7) or
severe sepsis (n = 47) developed in 50% of the patients, the
case-fatality rates of iGAS and iGCS/GGS disease at day 30
were only 10% and 2%, respectively. Table 3 shows initial
laboratory ﬁndings and clinical parameters of patients with
NF and SSTI. The six laboratory tests included are the same
as those on which a diagnostic scoring system for identiﬁca-
tion of NF patients [laboratory risk indicator for necrotizing
fasciitis (LRINEC) score] is based [23]. NF was associated
with higher values for initial pulse rate/C-reactive protein/
leucocytes/glucose/LRINEC score than the SSTI, but the only
signiﬁcant differences between the groups were a lower
systolic blood pressure and higher haemoglobin values in the
NF group compared to the SSTI group.
emm type, SAg gene proﬁle and presence of SlaA in relation
to clinical disease and outcome
Virulence gene proﬁle in relation to clinical iGAS and iGCS/
GGS disease are shown in Tables 4 and 5, respectively.
emm1, emm3, emm12, emm28, emm82 and emm89 accounted
for 81% of the GAS isolates. emm3 was associated with three
cases of NF that all developed STSS. emm1 was associated
with three cases of NF and two cases of STSS without NF.
emm3 (cellulitis, n = 1, NF + STSS, n = 1), emm12 (pneumo-
nia, n = 1) and emm28 (primary bactaeremia, n = 1, pneumo-
nia, n = 2) accounted for the six patients with iGAS disease
who died within 30 days after admission. The age of these
patients was in the range 60–86 years, and ﬁve of them had
a predisposing disease. SAg gene and SlaA proﬁles were
conserved within most of the GAS emm types, although ﬁve
TABLE 1. Clinical characteristics of invasive group A strep-
tococcal (iGAS) and invasive group C and group G strepto-
coccal (iGCS/GGS) disease
Number of
GAS (%),
n = 60a
Number of
GCS/GGS, (%)
n = 50 p-value
Clinical manifestations
STSS 6 (10) 1 (2) 0.122
Severe sepsis 29 (48) 18 (36) 0.180
Primary bacteremia 5 (8) 12 (24) 0.034b
SSTI 16 (27) 30 (60) 0.001c
NF 14 (23) 1 (2) 0.001b
Pneumonia 5 (8) 0 0.061
Puerperal sepsis 7 (12) 2 (4) 0.175
Otherd 14 (23) 7 (14) 0.235
Treatment and outcome
Mechanical ventilation 6 (10) 0 0.030b
Vasopressor treatment 9 (15) 4 (8) 0.375
Surgery 25 (42) 9 (18) 0.007b
30 day CFR 6 (10) 1 (2) 0.122
STSS, streptococcal toxic shock syndrome; NF, necrotizing fasciitis; SSTI, skin or
soft tissue infection; CFR, case-fatality rate.
aClinical information unavailable for one patient.
bStatistically signiﬁcant (Fisher’s exact test).
cStatistically signiﬁcant (chi-square test).
dTonsillitis and bacteraemia (GAS, n = 4), pyomyositis (GAS, n = 1), arthritis
(GAS, n = 3, GGS, n = 1), osteomyelitis (GCS, n = 1; GGS, n = 2), endocarditis
(GAS, n = 1; GGS, n = 2), peritonitis (GAS, n = 1; GGS, n = 1), salpingitis (GAS,
n = 1), meningitis (GAS, n = 2), unknown source of infection (GAS, n = 1).
TABLE 2. Demographic variables and risk factors associated
with invasive group A streptococcal (iGAS) and invasive
group C and group G streptococcal (iGCS/GGS) disease
Number of
GAS (%),
n = 60
Number of
GCS/GGS (%),
n = 50 p-value
Demographics
Female sex 35 (58) 20 (40) 0.056
Age < 15 years 2 (3) 0 0.500
Age 15–40 years 16 (27) 4 (8) 0.013b
Age 41–65 years 25 (42) 17 (34) 0.410
Age > 65 years 17 (29) 29 (58) 0.002c
Risk factorsa
One or more risk factors 42 (71) 47 (94) 0.002c
Skin lesion 32 (54) 31 (62) 0.442
Hospital acquired infections 5 (8) 5 (10) 1.000
Diabetes 5 (8) 6 (12) 0.751
Chronic heart disease 4 (7) 19 (38) <0.001b
Chronic lung disease 6 (10) 4 (8) 0.751
Chronic renal failure 2 (3) 2 (4) 1.000
Chronic liver disease 5 (8) 3 (6) 0.724
Alcoholism 2 (3) 2 (4) 1.000
Intravenous drug use 6 (10) 2 (4) 0.285
Cancer 11 (19) 13 (26) 0.366
Immunosuppression 7 (12) 5 (10) 1.000
aData on risk factors available for 59 out of 60 iGAS patients.
bStatistically signiﬁcant (Fisher’s exact test).
cStatistically signiﬁcant (chi-square test).
TABLE 3. Initial clinical ﬁndings and laboratory values asso-
ciated with necrotizing fasciitis (NF) and skin or soft tissue
infection (SSTI)
Clinical parameters and
initial laboratory values NF (n = 15) SSTI (n = 46) p-value
Systolic blood pressure (mmHg) 95 (76–125) 115 (70–205) 0.0169c
Pulse rate (per min) 105 (84–160) 97 (70–160) 0.0797
Temperature (C) 38.3 (36.8–41.0) 38.9 (35.4–41.0) 0.3657
C-reactive protein (mg/L) 188 (9–544) 80 (1–526) 0.1007
Leukocyte count (· 109/L) 15.9 (2.2–36.1) 13.1 (0.6–30.0) 0.7376
Haemoglobin (g/dL) 13.5 (10.6–16.7) 12.2 (9.6–16.6) 0.0471c
Creatinine (lmol/L) 83 (37–510) 83 (49–378) 0.3837
Sodium (mmol/L) 135 (128–145) 137 (128–143) 0.0772
Glucose (mmol/L)a 7.3 (4.2–14.2) 6.4 (4.4–15.4) 0.9189
LRINEC scoreb 5 (0–9) 3 (0–10) 0.1732
Values are expressed as the median (range). Pulse rate, temperature and labora-
tory values recorded on admission. Systolic blood pressure; the lowest value
recorded during the ﬁrst 48 h after admission. LRINEC, laboratory risk index
for necrotizing fasciitis.
aResults unavailable for ﬁve patients with SSTI.
bBased on values for C-reactive protein, leukocyte count, haemoglobin, creati-
nine, glucose and sodium [23]. Seven patients with NF (47%) and 11 patients
with SSTI (24%) had a LRINEC score ‡6.
cStatistically signiﬁcant (Mann–Whitney test).
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different proﬁles were detected among emm28 isolates.
All GAS associated with NF and/or STSS possessed speA,
speC or both of these genes. speA was signiﬁcantly associated
with GAS NF compared to GAS SSTI (p 0.001). Virulence
gene pairs speH-speI, speL-speM and speK-SlaA, encoded on
three different phages, were detected exclusively in pairs.
The most prevalent GCS/GGS emm type was stG643
(n = 11), and this type, together with stC74a, stG10, stG485,
stG6 and stG652, accounted for 77% of the GCS/GGS. Three
novel GGS emm subtypes were identiﬁed. Two of these
types were associated with particularly severe clinical disease
because one GGS of stC74a.2 caused cellulitis and STSS and
another GGS of stG485.2 caused vertebral osteomyelitis in a
terminal cancer patient, who died 20 days after admission.
speGdys was detected in 35 out of 48 GCS/GGS and was
restricted to certain emm types. Neither GAS SAg genes,
nor SlaA were detected in GCS/GGS.
Discussion
The data obtained in the present study indicate high rates
of both iGAS and iGCS/GGS disease in our community
throughout the study period. The rates of iGAS disease
were comparable to rates of 2.5–5.7 cases per 100 000 per
year that were recently observed in other western countries
[4,10,22,24,25]. The incidence of iGAS STSS was in line
with those reported from Canada, Denmark and Sweden
[10,22,25]. A considerable proportion of our iGAS patients
developed NF (23%; 3.5 per 100 000). In Alberta, Canada,
12% (1.7 per 100 000) of the patients with iGAS disease
developed NF during 2000–2002 [25] and, in large samples
from the USA and several European countries, NF accounted
for <10% of iGAS infections [2,3,24]. It is also noteworthy
that we found a considerably higher frequency of GAS NF
in our region compared to that reported from the total
Norwegian population during 2006–2007 [15]. The limited
temporal and geographical diversity and a high degree of
clinical awareness of NF at the hospitals in our community
might have lead to collection biases in the present study
compared to larger population-based studies. However, the
GAS NF cases were distributed throughout the study period,
and high rates of this clinical syndrome have previously been
reported in western Norway [26,27]. Therefore, we might
speculate that the incidence of NF caused by GAS is particu-
larly high in our community.
Severe local pain and signs of systemic toxicity are clinical
hallmarks of NF, although the paucity of early signs from skin
and soft tissue can make the clinical diagnosis difﬁcult.
Recently, the LRINEC score, based on selected laboratory
TABLE 4. Virulence gene proﬁle in relation to clinical manifestations of invasive group A streptococcal (iGAS) disease
emm type
Number
of isolates speA speC speG speH speI speJ speK speL speM ssa smeZ SlaA Clinical disease
emm1.0 9 + ) + ) ) + ) ) ) ) + ) NF (3), pneumonia + STSS (1), pneumonia
(1), meningitis (1), puerperal sepsis + STSS
(1) puerperal sepsis (1), tonsillitis and
bacteraemia (1)
emm3.1 9 + ) + ) ) ) + ) ) + + + NF + STSS (3), SSTI (1), salpingitis (1),
arthritis (1), pyomyositis (1), puerperal
sepsis (2)
1 + ) + ) ) ) ) ) ) + + ) Primary bacteraemia (1)
emm4.0 2 ) + ) ) ) ) ) ) ) + + ) SSTI (1), tonsillitis and bacteraemia (1)
emm9.0 1 ) ) + ) ) ) + ) ) ) + + Tonsillitis and bacteraemia (1)
emm12.0 5 ) + + + + ) ) ) ) ) + ) NF (1), SSTI (1), pneumonia (1),
meningitis + SSTI (1), arthritis (1)
1 ) ) + + + ) ) ) ) + + ) SSTI (1)
emm28.0 6 ) + + ) ) + ) ) ) ) + ) SSTI (3), puerperal sepsis (1), pneumonia
(1), primary bacteraemia (1)
4 ) + + ) ) + + ) ) ) + + Primary bacteraemia (1), pneumonia (1),
peritonitis (1), unknowna (1)
1 + + + ) ) + + ) ) ) + + NF + STSS (1)
1 ) ) + ) ) + + ) ) ) + + SSTI (1)
1 ) ) + ) ) + ) ) ) ) + ) SSTI (1)
emm75.0 3 ) + + ) ) ) + + + ) + + NF (1), tonsillitis and bacteraemia (1),
puerperal sepsis (1)
emm77.0 1 ) + ) ) ) ) ) ) ) ) + ) NF (1)
emm82.0 6 ) + + + + ) ) ) ) ) + ) NF (2), SSTI (2), endocarditis (1), primary
bacteraemia (1)
emm89.0 4 ) ) + ) ) ) ) ) ) ) + ) SSTI (2), arthritis (1), puerperal sepsis (1)
emm89.0 1 ) + + ) ) ) ) ) ) ) + ) SSTI (1)
emm102.0b 1 ) + + ) ) + ) ) ) ) + ) NF (1)
emm104.0 1 ) ) ) ) ) ) ) + + ) + ) Primary bactaeremia (1)
emm118.0 1 ) + + ) ) ) ) ) ) ) + ) SSTI (1)
Total 59 20 31 55 12 12 23 19 4 4 13 59 19
One GAS isolate associated with necrotizing fasciitis (NF) was not available for analysis. STSS, streptococcal toxic shock syndrome; SSTI, skin or soft tissue infection.
aClinical information unavailable.
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values, was proposed as a robust tool for distinguishing NF
from SSTI [23]. The results from that study indicated that a
LRINEC score ‡6 was highly suggestive of NF. Only seven
out of 15 NF cases in our material reached this cut-off value
of 6. Hence, we recommend a meticulous clinical approach
and a low threshold for early surgical exploration when soft
tissue necrosis is suspected.
Results from recent studies have indicated that the burden
of iGCS/GGS disease previously has been under-recognized
[3–6]. In line with these reports, we found a high incidence
of iGCS/GGS disease. iGCS/GGS infections were associated
with older patients, a higher frequency of comorbidities and
SSTI and a lower incidence of NF than iGAS disease, similar
to the ﬁndings obtained in a Danish study [3]. However, in a
survey on streptococcal disease from Japan during 2006–
2007, the rates of NF and cellulitis in the iGCS/GGS group
were equal to those among iGAS cases [6]. Our iGAS
patients needed surgery and mechanical ventilation more
often than the iGCS/GGS patients, probably as a result of
the frequent occurrence of severe manifestations among
patients with iGAS disease. Yet, the case-fatality rate was
relatively low, even among iGAS cases. We consider that this
is partly explained by the early recognition and treatment of
the most severe clinical syndromes, including surgical
debridement of necrotic tissue.
We used emm typing and SAg gene and SlaA proﬁling to
characterize our isolates. Multilocus sequence typing (MLST)
has gained popularity in epidemiological surveys on b-haemo-
lytic streptococci, and results from recent studies indicate a
frequent concordance between GAS emm type and MLST
proﬁle [14,15,28]. Such a correlation also appears to exist
among isolates belonging to certain GCS/GGS emm types
[29]. Given these observations and our focus on virulence
associated genes, MLST was not applied on our streptococ-
cal sample.
Relatively few emm types dominated among both iGAS
and iGCS/GGS isolates in our material. The most prevalent
GAS emm types (emm1, emm3, emm28) were linked to
severe disease or fatal outcome. These types have been
dominant in previous studies on iGAS disease, and both
emm1/M1 and emm3/M3 have been signiﬁcantly associated
with NF, STSS or death [2,24,25]. emm1 and emm28 were
highly prevalent types in Norway during 2006–2007 [15].
emm3 was associated with only 6% of iGAS cases in that
material, indicating an over-representation of this type in our
community compared to the total Norwegian population. Six
emm types accounted for almost 80% of the iGCS/GGS
isolates. The most prevalent type, stG643, was frequently
reported in a survey from the USA during 2002–2005, but
absent from a sample collected in Japan [6,29], illustrating
that predominant types vary with geographical location.
Phages are probably the primary means of lateral genetic
exchange between b-haemolytic streptococci and contribute
to strain diversiﬁcation and enhancement of virulence. In the
present study, GAS isolates belonging to emm28 were asso-
ciated with ﬁve distinct SAg gene proﬁles. Among the other
GAS isolates, we found a close linkage between emm type
and the SAg gene proﬁle. Similar results have been reported
previously [15,30], and it has been speculated that a biologi-
cal interaction between M protein and phages might partly
explain the differences in phage receptiveness among isolates
belonging to different emm types [30]. Hence, the over-
representation of speA in GAS causing NF compared to GAS
associated with SSTI merely appeared to reﬂect the genetic
armament of isolates belonging to emm1 and emm3. The
presence of SlaA was also, in line with a previous report,
restricted to certain emm types, including emm3, emm28 and
emm75 [31]. We detected speGdys in the majority (but not
all) of the GCS/GGS isolates, and its presence was conﬁned
to certain emm types. speGdys shares a high degree of similar-
ity with speG in GAS, and was detected in only two out of
46 iGCS/GGS isolates in a recent study [32]. This might indi-
cate that speGdys is situated on an unstable chromosomal
location or that some alleles of this gene are not detected
by PCR as a result of mutations at primer annealing sites.
TABLE 5. Virulence gene proﬁle in relation to clinical mani-
festations of invasive group C and group G streptococcal
(iGCS/GGS) disease
emm type
Number of
isolates speGdys Clinical disease
stC5345.1 1 ) SSTI (1)
stC74a.0 4 + SSTI (2), peritonitis (1),
endocarditis (1)
stC74a.2a 1 + SSTI + STSS
stG10.0 5 + SSTI (3), primary bacteraemia (2)
stG245.0 1 ) SSTI (1)
stG2078.0 2 ) SSTI (2)
stG2574.1a 1 + Puerperal sepsis (1)
stG480.0 2 + SSTI (1), primary bacteraemia (1)
stG485.0 5 + SSTI (3), puerperal sepsis (1),
primary bacteraemia (1)
stG485.2a 1 + SSTI + vertebral osteomyelitis
stG5420.0 1 ) Primary bacteraemia
stG6.0 4 + SSTI (2), endocarditis (1), primary
bacteraemia (1)
stG6.1 2 ) SSTI (2)
stG643.0 6 ) SSTI (4), primary bacteraemia (2)
1 + SSTI (1)
stG643.1 4 + SSTI (2), primary bacteraemia (1),
arthritis (1)
stG652.0 4 + SSTI (3), primary bacteraemia (1)
stG62647.0 2 + SSTI + vertebral osteomyelitis (1),
primary bacteraemia (1)
stG840.0 1 + Primary bacteraemia (1)
Total 48 35
Two GCS/GGS isolates associated with osteomyelitis or necrotizing fasciitis
were not available for analysis. STSS, streptococcal toxic shock syndrome; SSTI,
skin or soft tissue infection.
aNew emm subtype.
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The pathogenetic role of speGdys is uncertain because previ-
ous results do not indicate that severe human disease caused
by GCS/GGS is associated with superantigen mitogenicity
[32].
In summary, the burden of invasive b-haemolytic strepto-
coccal disease was signiﬁcant in our community during the
study period. The high incidence of skin and soft tissue
infections prompts the need for investigations of host and
microbe interactions in NF and SSTI.
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